Latest market price
307.02
-15.73-4.87%
LGNDQT63Ligand Pharmaceuticals Incorporated·NASDAQ
307.02-4.87%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index—P/E137.06EPS (ttm)2.24Insider Own5.52%Shs Outstand19.94MPerf Week-0.42%
Market Cap6.12BForward P/E24.78EPS next Y12.39Insider Trans-7.74%Shs Float19.52MPerf Month1.34%
Enterprise Value6.80BPEG6.78EPS next Q2.88Short Float12.82%Perf Quarter2.07%
Income53.00MP/S24.00EPS this Y25.61%Short Ratio9.96Perf Half Y34.45%
Sales255.00MP/B6.36EPS next Y30.15%ROA2.30%Short Interest2.50MPerf YTD62.38%
Book/sh48.26P/C13.69EPS next 5Y20.21%ROE5.22%52W High326.63 -6.00%Perf Year64.13%
Cash/sh22.42P/FCF68.01EPS past 3/5Y—ROIC2.29%52W Low175.89 74.55%Perf 3Y501.29%
Dividend Est.—EV/EBITDA83.97Sales past 3/5Y10.99% 10.32%Gross Margin—Volatility3.86% 3.66%Perf 5Y259.38%
Dividend TTM—EV/Sales26.67EPS Y/Y TTM8.21%Oper. Margin11.91%ATR (14)11.12Perf 10Y426.35%
Dividend Ex-DateJul 02, 2010Quick Ratio13.35Sales Y/Y TTM1.59%Profit Margin20.27%RSI (14)51.14Recom2.33
Dividend Gr. 3/5Y-63.47% —Current Ratio13.35EPS Q/Q-13.59%SMA200.56%Beta1.22Target Price342.00
Payout0.00%Debt/Eq1.17Sales Q/Q-31.30%SMA503.44%Rel Volume1.10Prev Close322.75
Employees47LT Debt/Eq1.17EarningsFeb 25SMA20021.25%Avg Volume240.35KPrice307.02
IPO DateNov 18, 1992Option/ShortYes / YesEPS/Sales Surpr.14.66% 2.26%Net Debt/EBITDA8.41Volume265,433Change-4.87%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-29-26ReiteratedStifel Nicolaus$332 → $350
Sep-25-26ReiteratedBarclaysOverweight$345
Aug-14-26InitiatedLeerinkOutperform$330
Aug-06-26ReiteratedHC Wainwright & Co.Buy$289 → $358
Aug-03-26ReiteratedOppenheimerOutperform$275 → $326
Jul-20-26ReiteratedCraig-HallumBuy$330 → $345
Jul-15-26ReiteratedRBC CapitalOutperform$252 → $340
Jul-08-26ReiteratedStifel Nicolaus$255 → $332
Apr-30-26ReiteratedHC Wainwright & Co.Buy$243 → $289
Apr-28-26ReiteratedRBC CapitalOutperform$130 → $252
Latest News· Times ET
Oct-30-26
Oct-29-26
Oct-27-26
Oct-23-26
Oct-22-26
Oct-22-2604:01PM
Oct-19-26
Oct-15-26
Oct-13-26
Oct-07-26
Sep-29-26
Sep-28-26
Sep-24-26
Sep-22-26
Company

Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue255268167131—————
Cost of Goods Sold Incl. D&A-1871135—————
Gross Profit27226115696—————
Selling, General and Administrative Excl. Other148927953—————
Research and Development24812125—————
Other Operating Expense7041796—————
Operating Income3047-2312—————
Interest Expense6531—————
Unusual Expense
—————————
Non-Operating Income (Expense)281162852—————
Net Income Before Taxes53159364—————
Income Taxes135710—————
Consolidated Net Income53124-452—————
Net Income From Continuing Operations53124-454—————
Net Income53124-452—————
EPS (Recurring)2.596.44-0.223.02—————
EPS (Basic, Before Extraordinaries)2.596.44-0.223.02—————
EPS (Diluted)2.246.13-0.222.94—————
EBITDA8119341101—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio137.0630.84—24.29—————
Price To Sales Ratio24.0813.4011.559.27—————
Gross Margin106.6797.3993.4173.28—————
Operating Margin11.7617.54-13.779.16—————
Net Margin20.7846.27-2.4039.69—————
Shares Outstanding20191817—————
Market Capitalization6,1403,5921,9291,214—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$347.34$294.06$240.77$187.48$134.20● Close Price0.00M3.19M6.39M9.58M12.78MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Reardon AndrewCLO & SecretaryOct 02 '26Option Exercise52.2734017,77236,854Oct 06
Reardon AndrewCLO & SecretaryOct 02 '26Sale304.075,0001,520,34631,854Oct 06
Zimmermann MartineDirectorSep 10 '26Sale285.001,200342,0003,897Sep 14
Reardon AndrewCLO & SecretarySep 03 '26Sale286.095,0001,430,43536,514Sep 08
Espinoza OctavioChief Financial OfficerAug 12 '26Option Exercise56.9131,6411,800,57559,337Aug 14
Espinoza OctavioChief Financial OfficerAug 12 '26Sale292.0631,6419,241,22927,696Aug 14
Haas JasonDirectorAug 12 '26Option Exercise51.566,138316,47511,119Aug 14
Haas JasonDirectorAug 12 '26Sale292.817,1382,090,0623,981Aug 14
Reardon AndrewCLO & SecretaryAug 03 '26Sale288.995,0001,444,95141,514Aug 04
Reardon AndrewCLO & SecretaryAug 03 '26Option Exercise52.275,000261,35046,514Aug 04
Reardon AndrewCLO & SecretaryJul 01 '26Option Exercise52.275,000261,35046,514Jul 06
Reardon AndrewCLO & SecretaryJul 01 '26Sale313.285,0001,566,37741,514Jul 06
Sabba Stephen LDirectorJun 16 '26Sale254.002,145544,83033,629Jun 18
Sabba Stephen LDirectorJun 16 '26Option Exercise66.132,145141,84935,774Jun 18
Haas JasonDirectorJun 12 '26Sale255.586,4611,651,3204,981Jun 15
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.